'Sexual Chocolate' Faces Recalls After FDA Tests Reveal Undisclosed Viagra

FDA Testing Uncovers Hidden Pharmaceutical Drugs in Popular Sexual Enhancement Products

A growing wave of voluntary recalls is sweeping through the sexual enhancement supplement market after the U.S. Food and Drug Administration (FDA) conducted laboratory testing that revealed a troubling secret: products marketed as natural supplements were found to contain undisclosed active pharmaceutical ingredients — specifically sildenafil and tadalafil, the drugs more commonly known by their brand names Viagra and Cialis. Products with provocative names like Boner Bears, DTF, and Sexual Chocolate are among those now being pulled from shelves, raising serious questions about consumer safety, regulatory oversight, and the booming market for over-the-counter sexual health products.

What the FDA Found — and Why It Matters

Sildenafil and tadalafil are prescription-only medications approved by the FDA to treat erectile dysfunction and, in some cases, pulmonary arterial hypertension. These drugs work by inhibiting a specific enzyme — phosphodiesterase type 5 (PDE5) — which causes blood vessels to relax and increases blood flow. While effective for many men when prescribed and monitored by a physician, these compounds carry significant risks when taken without medical supervision.

The core issue with these recalls is not simply that the products contain pharmaceutical-grade drugs — it is that consumers were never told. Labels on these products made no mention of sildenafil or tadalafil, meaning buyers had no way of knowing they were ingesting a controlled prescription substance. For a wide range of people, this hidden ingredient could have serious, even life-threatening consequences.

Who Is Most at Risk?

Undisclosed sildenafil and tadalafil pose particularly serious dangers to several groups of consumers:

• People taking nitrates — a class of drugs commonly prescribed for heart conditions such as angina — face a potentially fatal drop in blood pressure when combined with PDE5 inhibitors. The interaction can trigger a cardiovascular emergency.
• Individuals with underlying heart disease may not be cleared for sexual activity at all, and a hidden stimulant drug in a candy or gummy supplement could push them into dangerous territory without any warning.
• People with kidney or liver disease may metabolize these drugs more slowly, leading to toxic accumulation in the body.
• Those already using erectile dysfunction medications could unknowingly double their dose, dramatically amplifying side effects including severe headaches, vision changes, and priapism — a prolonged, painful erection that constitutes a medical emergency.

The fact that many of these products are sold in convenience stores, gas stations, and online marketplaces — often without any meaningful age verification or pharmacist consultation — makes the risk exposure extraordinarily broad.

The Products Involved: A Look at the Recalled Brands

The recalls encompass a colorful and deliberately provocative lineup of products designed to appeal to consumers seeking a discreet, accessible boost to sexual performance. Boner Bears, which markets itself in the format of gummy bear candies, is among the most recognizable names in the recall list. Its child-friendly packaging format alongside potent hidden pharmaceutical content raises additional layers of concern for regulators and child safety advocates.

DTF — an acronym widely understood as slang for sexual availability — and Sexual Chocolate round out a category of products that rely heavily on humor, bold branding, and word-of-mouth marketing to reach their target demographics. These brands have cultivated significant online followings through social media platforms, which has amplified both their market reach and the potential impact of the recalls.

All of the affected sellers have issued voluntary recalls following the FDA's findings. Voluntary recalls, while an important mechanism in the regulatory system, do place the burden of action primarily on the companies themselves and depend heavily on consumer awareness to be effective. Many consumers who already purchased these products may not learn about the recall at all unless they actively follow news coverage or receive direct outreach from retailers.

The Broader Problem: Supplements and the Regulatory Gap

This situation is far from unprecedented. The FDA has documented hundreds of cases over the years in which dietary supplements — particularly those marketed for sexual enhancement, weight loss, and athletic performance — were found to contain hidden pharmaceutical drugs or other undisclosed active compounds. Unlike prescription drugs, dietary supplements in the United States are not required to undergo rigorous pre-market approval testing by the FDA. Manufacturers are largely responsible for ensuring the safety and accurate labeling of their own products before bringing them to market.

This regulatory gap creates an environment in which bad actors — whether knowingly deceptive or negligently careless — can introduce dangerous products to consumers who believe they are making a safe, natural choice. The sexual enhancement supplement segment is one of the most frequently flagged categories in the FDA's ongoing monitoring program, known as the Tainted Products Marketed as Dietary Supplements database.

What Regulators Are Doing

In response to this ongoing pattern, the FDA has been expanding its testing programs and issuing increasingly detailed public warnings. The agency encourages consumers to report adverse events associated with supplement use through its MedWatch Safety Reporting Portal. Additionally, the FDA works with the Federal Trade Commission (FTC) to pursue enforcement actions against companies that make deceptive health claims or distribute adulterated products.

Some consumer advocates and medical professionals have called for stronger pre-market testing requirements for supplements in categories historically linked to adulteration, arguing that voluntary recalls and post-market surveillance are insufficient to protect public health in a market that generates billions of dollars annually.

What Consumers Should Do Right Now

If you have purchased any of the recalled products — including Boner Bears, DTF, Sexual Chocolate, or similar sexual enhancement supplements — the FDA advises you to stop using them immediately. Do not consume any remaining product. If you have experienced any unusual symptoms such as chest pain, dizziness, sudden changes in blood pressure, or vision disturbances after use, seek medical attention promptly and inform your healthcare provider of what you took.

Consumers can check the FDA's official website and its recall database at fda.gov/recalls for the most up-to-date list of affected products and lot numbers. When in doubt about any supplement, speaking with a licensed pharmacist or physician before use remains the safest course of action — particularly for anyone managing a chronic health condition or taking prescription medications.

The Takeaway: Buyer Beware in the Supplement Aisle

The recalls of Sexual Chocolate, Boner Bears, and DTF serve as a sharp reminder that the dietary supplement market, despite its veneer of natural wellness, can harbor serious pharmaceutical risks. When products carry no prescription requirement and face limited pre-market scrutiny, the burden of vigilance falls disproportionately on consumers — many of whom reasonably assume that what they buy off a shelf or online has been verified as safe. These recalls make clear that assumption can be dangerously wrong. Staying informed, verifying products against the FDA's tainted supplement database, and consulting healthcare professionals before trying any new supplement are the most reliable ways to protect yourself in a market that regulators are still working hard to keep safe.